Abstract
NF-κB essential modulator (NEMO), the non-catalytic regulatory subunit of the IκB kinase (IKK) complex, is essential for the canonical NF-κB activation pathway. It has been identified as a molecular platform for assembling the IKK complex and recruiting upstream IKK activators. However, the exact mechanism for regulating IKK activity has still remained elusive. This review describes structural and functional characteristics of NEMO protein, covers the feasible polyubiquitin-mediated NEMO-dependent IKK complex activation mechanism, and briefly summarizes some proteins that bind to NEMO for enhancing or suppressing IKK complex activity. Furthermore, it also discusses several bioactive compounds that disrupt the protein-protein interactions (PPI) involving NEMO, as these PPI may act as alternative routes to develop novel pharmacological agents for inflammation and cancer therapy.
Keywords: IKKγ/NEMO, IKK activation model, K63-linked polyubiquitin chains, linear polyubiquitin chains, NEMO-binding domain (NBD), oligomerzation states, protein-protein interactions.
Current Drug Targets
Title:Insights into Targeting NEMO for Pharmacological Regulation
Volume: 15 Issue: 9
Author(s): Hong-Xi Chu, Jun-Feng Zhu, Jing-Jie Huang, Zheng-Yu Jiang, Meng-Chen Lu, Xiao-Jin Zhang, Hao-Peng Sun and Qi-Dong You
Affiliation:
Keywords: IKKγ/NEMO, IKK activation model, K63-linked polyubiquitin chains, linear polyubiquitin chains, NEMO-binding domain (NBD), oligomerzation states, protein-protein interactions.
Abstract: NF-κB essential modulator (NEMO), the non-catalytic regulatory subunit of the IκB kinase (IKK) complex, is essential for the canonical NF-κB activation pathway. It has been identified as a molecular platform for assembling the IKK complex and recruiting upstream IKK activators. However, the exact mechanism for regulating IKK activity has still remained elusive. This review describes structural and functional characteristics of NEMO protein, covers the feasible polyubiquitin-mediated NEMO-dependent IKK complex activation mechanism, and briefly summarizes some proteins that bind to NEMO for enhancing or suppressing IKK complex activity. Furthermore, it also discusses several bioactive compounds that disrupt the protein-protein interactions (PPI) involving NEMO, as these PPI may act as alternative routes to develop novel pharmacological agents for inflammation and cancer therapy.
Export Options
About this article
Cite this article as:
Chu Hong-Xi, Zhu Jun-Feng, Huang Jing-Jie, Jiang Zheng-Yu, Lu Meng-Chen, Zhang Xiao-Jin, Sun Hao-Peng and You Qi-Dong, Insights into Targeting NEMO for Pharmacological Regulation, Current Drug Targets 2014; 15 (9) . https://dx.doi.org/10.2174/1389450115666140804215119
DOI https://dx.doi.org/10.2174/1389450115666140804215119 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Signaling Epicenters: The Role of Caveolae and Caveolins in Volatile Anesthetic Induced Cardiac Protection
Current Pharmaceutical Design Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Animal Models to Investigate Pathomechanisms and Evaluate Novel Treatments for Autoimmune Bullous Dermatoses
Current Pharmaceutical Design Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design VFP: A Visual Algorithm for Predicting Gene Fusion in RNA-Seq Data
Current Bioinformatics Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology
Current Drug Metabolism Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design Organ Preservation by the Association of Chemotherapy and Radiotherapy in Invasive Bladder Cancer
Current Drug Therapy Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Editorial [Hot Topic: Novel Kinase Inhibitors in Cancer Therapy (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy
Current Gene Therapy Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Antiviral Properties of Glycyrrhizic Acid and its Semisynthetic Derivatives
Mini-Reviews in Medicinal Chemistry Ligand-modified Biopolymeric Nanoparticles as Efficient Tools for Targeted Cancer Therapy
Current Pharmaceutical Design